Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stada Generics Takes A Hit Even As Firm Steals A March On Rivals

Group’s Sales ‘Better Than The Average For The Top-Five Suppliers’

Executive Summary

Stada saw a small drop in both sales and profitability for its Generics division, but insisted the firm’s “strong position in generics,” alongside its leading position in consumer healthcare and growing specialty offering, “put the group on a sustainable growth course.”

You may also be interested in...



Stada And NTC Ally On MENA Ophthalmic Brands

Stada has struck a deal to partner with Italy’s NTC to market a portfolio of ophthalmic brands in the MENA region. At the same time, the German generics giant has agreed a distribution deal for the Czech Republic with Latvia’s Kalceks.

Stada Expands Portfolio In US And Nordics As First-Half Sales Rise

Stada reported Branded Products sales up 9% in the first half as it secured two additions to its portfolio, with a US dietary supplement brand and Nordic herbal analgesic.

Stada Partners With Calliditas On Novel Budesonide Formulation

Stada has struck a licensing and commercialization deal with Calliditas worth more than $100m to partner on a novel oral formulation of budesonide to treat Immunoglobulin A Nephropathy in Europe.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel